Search | Clinical Trials Finder

Conditions: Ulcerative Colitis (UC), Crohn's Disease
Interventions: Risankizumab, Cytochrome P450 (CYP) Substrates; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 4
States / cities: Coronado, California • DeLand, Florida • Margate, Florida + 1 more

Conditions: Bullous Keratopathy, Corneal Erosion, Entropion, Corneal Edema, Corneal Dystrophy, Corneal Ulcer, Foreign Body in Cornea, Bell Palsy, Keratoconjunctivitis, Filamentary Keratitis, Sicca Syndrome; Keratoconjunctivitis (Etiology)
Interventions: Lotrafilcon A contact lenses; Device
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: Orlando, Florida • Franklin Park, Illinois • Memphis, Tennessee

Conditions: Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome, HIV Infection
Interventions: Thalidomide; Drug
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Behcet Syndrome
Interventions: Tocilizumab; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Oral Mucositis Due to Chemotherapy
Interventions: Dexamethasone Mouthwash; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Oral Mucositis, Nausea, Vomiting, Diarrhea
Interventions: ProThelial; Device
Lead sponsor: Ashley Downs Bioscience; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Foster, Rhode Island

Conditions: Diabetic Foot Ulcers
Interventions: ofloxacin, MSI-78; Drug
Lead sponsor: Abeona Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1996
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis
Interventions: Biospecimen Collection, Cabozantinib, Fluoropyrimidine, Ipilimumab, Nivolumab, Platinum Compound, Platinum Doublet; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 51
States / cities: Birmingham, Alabama • Palo Alto, California • Sacramento, California + 37 more

Conditions: Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions: Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation; Drug · Biological
Lead sponsor: Ari M Grinspan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease
Interventions: Sucralfate, Placebo, Acetaminophen, Ibuprofen; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 6 Months to 5 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Mild to Moderately Active Ulcerative Colitis
Interventions: Polyphenon E®, Placebo Oral Tablet; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Behcet Syndrome, Behcet Disease
Interventions: Topical Pentoxifylline Gel (Vehicle +PTX), Topical Placebo Gel (Vehicle); Drug
Lead sponsor: Silk Road Therapies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Ulcerative Colitis
Interventions: Blood sampling, endoscopy, budesonide-MMX® 6 mg, budesonide-MMX® 9 mg, Placebo, Asacol® 400 mg; Procedure · Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more

Conditions: Ulcerative Colitis
Interventions: RPC1063, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 113
States / cities: Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more

Conditions: LAD1
Interventions: Ustekinumab; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 110 Years
Enrollment: 114 participants
Timeline: 1995 – 2020
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ulcerative Colitis
Interventions: Herbal treatment (SA100); Drug
Lead sponsor: Stanford University; Other
Eligibility: 13 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis
Interventions: Combination Oral Budesonide and Rectal Hydrocortisone; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Corneal Ulcer, Eye Infections, Fungal
Interventions: Voriconazole, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 16 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ulcerative Colitis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more

Conditions: Ulcerative Colitis
Interventions: NX-13 250mg IR, NX-13 500mg IR, NX-13 500mg MR, Placebo; Drug
Lead sponsor: Landos Biopharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 22
States / cities: Huntsville, Alabama • Lancaster, California • Mission Viejo, California + 18 more

Conditions: Aphthous Ulcer
Interventions: PBM Therapy, Maalox plus Benadryl; Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 5 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Oral Mucositis (Ulcerative), Oral Mucositis (Ulcerative) Due to Radiation, Oral Mucositis (Ulcerative) Due to Antineoplastic Therapy, Head and Neck Cancer
Interventions: Photobiomodulation, Routine Oral Care and Analgesia; Device · Other
Lead sponsor: MuReva Phototherapy Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • Long Beach, California • Miami, Florida + 9 more

Search by objective public record fields.

A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

AONDA Therapeutic Indication Study I

Thalidomide to Treat Oral Lesions in HIV-Infected Patients

Tocilizumab for the Treatment of Behcet's Syndrome

Using a Steroid Mouthwash to Prevent Mouth Sores During Chemotherapy

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis

The Use of Oral Budesonide and Rectal Hydrocortisone for the Treatment of Active Ulcerative Colitis

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis

Effects of Photobiomodulation (PBM) on Pain After Presentation of Aphthous Ulcers in Pediatric Dental Patients

Photobiomodulation to Demonstrate Safety and Reduce the Incidence of Oral Mucositis in Adult Head & Neck Cancer Patients